Trial Profile
UNDERSTANDING HEMOPHILIA A AND B DRUG DOSAGE ADMINISTRATION PATTERNS
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 May 2019
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary) ; Moroctocog alfa (Primary) ; Nonacog alfa (Primary) ; Rurioctocog alfa pegol (Primary) ; Blood coagulation factor replacements
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Sponsors Pfizer
- 05 Apr 2018 Status changed from recruiting to discontinued.
- 05 Mar 2018 Planned number of patients changed from 300 to 200.
- 13 Dec 2017 Status changed from active, no longer recruiting to recruiting.